Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.41 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.39 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.39 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.39 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.39 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.39 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.39 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.38 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17061753 | 0.84 | LMNA (0.41) | LMNATP53HTTMDM2PDE2A | |
| SCHEMBL423349 | 0.84 | KCNH2 (0.45) | LMNATP53HTTKCNH2PSEN1 | |
| SCHEMBL24986362 | 0.84 | KCNH2 (0.39) | LMNATP53HTTMDM2PDE2A | |
| SCHEMBL6816256 | 0.83 | LMNA (0.64) | LMNATP53HTTMDM2PDE2A | |
| SCHEMBL17553268 | 0.83 | LMNA (0.39) | LMNATP53HTTMDM2PDE2A | |
| SCHEMBL20216450 | 0.83 | DPP4 (0.40) | LMNATP53HTTMDM2PDE2A | |
| SCHEMBL23212834 | 0.83 | PDE2A (0.59) | LMNATP53HTTMDM2PDE2A | |
| SCHEMBL22855048 | 0.83 | LMNA (0.64) | LMNATP53HTTMDM2PDE2A | |
| SCHEMBL21239903 | 0.83 | LMNA (0.39) | LMNATP53HTTMDM2PDE2A | |
| SCHEMBL17069211 | 0.83 | DPP4 (0.40) | LMNATP53HTTMDM2PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 370 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043613-B2 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043613-B2 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12030869-B2 | 5-membered heteroaryl carboxamide compounds for treatment of HBV | ASSEMBLY BIOSCIENCES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20230399299-A1 | ALDH-2 INHIBITOR COMPOUNDS AND METHODS OF USE | AMYGDALA NEUROSCIENCES, INC. (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230399299-A1 | ALDH-2 INHIBITOR COMPOUNDS AND METHODS OF USE | AMYGDALA NEUROSCIENCES, INC. (US) | 2023-12-14 | — | — | US | disclosed |
| WO-2023227697-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023227698-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023227696-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023220223-A1 | INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMOVIRUS | MERCK SHARP & DOHME LLC (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20230365531-A1 | INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMO VIRUS | MERCK SHARP & DOHME LLC (US) | 2023-11-16 | — | — | US | disclosed |
| US-20090042836-A1 | e.g. 1-({[(2,3-difluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid; anticarcinogenic, antiproliferative agent | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-02-12 | — | — | US | disclosed |
| US-20080275052-A1 | HETEROBICYCLIC COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-11-06 | — | — | US | disclosed |
| US-7442830-B1 | Proteasome inhibitors | MILLENIUM PHARMACEUTICALS, INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-7323567-B2 | RSV polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2008-01-29 | — | — | US | disclosed |
| US-20070225317-A1 | RSV POLYMERASE INHIBITORS | SIMONEAU BRUNO | 2007-09-27 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070149506-A1 | Azepine inhibitors of Janus kinases | INCYTE CORPORATION | 2007-06-28 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-20070135467-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275052-A1 | HETEROBICYCLIC COMPOUNDS USEFUL AS KINASE INHIBITORS | MAP2K2, MAP2K6, MAP2K1 | LMNA 2399/4885TP53 2435/4885HTT 4753/4885 |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | LMNA 170/4885TP53 1637/4885HTT 3632/4885 |
| US-20230365531-A1 | INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMO VIRUS | METAP1, SARS1, RTF1 | LMNA 2519/4885TP53 3653/4885HTT 4009/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | LMNA 170/4885TP53 1637/4885HTT 3632/4885 |
| US-20070135467-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | LMNA 170/4885TP53 1637/4885HTT 3632/4885 |
| US-12043613-B2 | Inhibitors of SARM1 | SARM1, SMN1; SMN2, SARNP | LMNA 1340/4885TP53 2807/4885HTT 923/4885 |
| US-20070225317-A1 | RSV POLYMERASE INHIBITORS | POLR2E, POLR2H, POLR2A | LMNA 2603/4885TP53 3411/4885HTT 3903/4885 |
| US-20090042836-A1 | e.g. 1-({[(2,3-difluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid; anticarcinogenic, antiproliferative agent | PSMB1, PSMB11, PSMB5 | LMNA 1841/4885TP53 84/4885HTT 751/4885 |
| US-20230399299-A1 | ALDH-2 INHIBITOR COMPOUNDS AND METHODS OF USE | ALDH1A1, ALDH2, ALDH3A1 | LMNA 4278/4885TP53 4845/4885HTT 1910/4885 |
| US-20070149506-A1 | Azepine inhibitors of Janus kinases | JAK1, JAK3, JAK2 | LMNA 4785/4885TP53 727/4885HTT 4089/4885 |
| US-12030869-B2 | 5-membered heteroaryl carboxamide compounds for treatment of HBV | HCCS, HAVCR2, MAVS | LMNA 1876/4885TP53 65/4885HTT 3334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.